Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Affiliations

¹ Department Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
² Department of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
³ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
⁴ Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, USA.
⁵ Department of Immunology, University of Toronto, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶ Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
⁷ Department Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. m-van-den-brink@ski.mskcc.org.
⁸ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. m-van-den-brink@ski.mskcc.org.

Published Erratum

Johannes L Zakrzewski et al. Nat Biotechnol. 2024 Apr.

. 2024 Apr;42(4):674.

doi: 10.1038/s41587-024-02205-3.

¹ Department Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
² Department of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
³ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
⁴ Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, USA.
⁵ Department of Immunology, University of Toronto, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶ Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
⁷ Department Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. m-van-den-brink@ski.mskcc.org.
⁸ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. m-van-den-brink@ski.mskcc.org.

No abstract available

Erratum for

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MR. Zakrzewski JL, et al. Nat Biotechnol. 2008 Apr;26(4):453-61. doi: 10.1038/nbt1395. Epub 2008 Mar 30. Nat Biotechnol. 2008. PMID: 18376399 Free PMC article.